PDGFRB and neoplasm: Multi-kinase inhibitor that targets angiogenesis (VEGFR-1, -2, -3, TIE2), as well as oncogenesis (KIT, RET, RAF-1, BRAF, BRAF V600E), metastasis (VEGFR3, PDGFR, FGFR) and tumor immunity (CSF1R)